Random samples or the entire workforce in nine offices which similar clerical work was being performed were studied using a doctor administered questionnaire that inquired into symptoms have been linked with "sick building syndrome." Five of fully air conditioned, one had recirculation and mechanical ventilation, three naturally ventilated. Workers conditioned ventilated buildings interviewed blind. Seven at our request absence any known problem. Comparison prevalences between other showed...

Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment.We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant. We assigned adults with migraine, or without aura, in 1:1:1 ratio receive initial dose placebo, ubrogepant at 50 mg, 100 mg treatment single attack, option take second dose. The coprimary efficacy end points were freedom from pain 2 hours after absence most bothersome...

Ubrogepant is an oral calcitonin gene-related peptide receptor antagonist under investigation for acute treatment of migraine.To evaluate the efficacy and tolerability ubrogepant compared with placebo a single migraine attack.Phase 3, multicenter, randomized, double-blind, placebo-controlled, single-attack, clinical trial (ACHIEVE II) conducted in United States (99 primary care research clinics; August 26, 2016-February 2018). Participants were adults or without aura experiencing 2 to 8...

Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist that being investigated for the preventive treatment of migraine.In a phase 3, double-blind trial, we randomly assigned adults with 4 to 14 migraine days per month in 1:1:1:1 ratio receive once-daily dose oral atogepant (10 mg, 30 or 60 mg) placebo 12 weeks. The primary end point was change from baseline mean number across Secondary points included headache month, reduction at least 50% 3-month average...

To evaluate the long-term safety and tolerability of ubrogepant for acute treatment migraine.Ubrogepant is an oral, calcitonin gene-related receptor antagonist in development migraine. The efficacy was demonstrated 2 phase 3 trials which a significant improvement observed migraine headache pain, migraine-associated symptoms, ability to function.This 3, multicenter, randomized, open-label, 52-week extension trial. Adults with or without aura entered trial after completing one lead-in were...

Abstract Objective To assess long‐term safety, tolerability, and efficacy of once‐daily oral atogepant 60 mg in adults with migraine. Background Atogepant is an oral, small‐molecule, calcitonin gene–related peptide receptor antagonist approved for the preventive treatment episodic Methods A 52‐week, multicenter, randomized, open‐label trial (18–80 years) Lead‐in completers or newly enrolled participants 4–14 migraine days/month were randomized (5:2) to once daily standard care (SC)...

A cross sectional survey investigating "building sickness" was carried out in two buildings with similar populations of office workers but differing ventilation systems, one being fully air conditioned humidification and the other naturally ventilated. The prevalence symptoms related to work assessed by a questionnaire administered doctor. stratified, randomly selected sample seen (84% response). Building sickness includes several distinct syndromes work, most which were significantly more...

Background Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist for the preventive treatment of migraine. Methods In double-blind, phase 3 ADVANCE trial, participants with 4–14 migraine days/month were randomized to atogepant 10 mg, 30 60 or placebo once daily 12 weeks. We evaluated time course efficacy Analyses included change from baseline in mean monthly days during each three 4-week periods, weekly weeks 1–4, and proportion a on day first week....

Background Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate long-term safety tolerability atogepant in participants who completed phase 3 ADVANCE trial (NCT03777059). Methods This 40-week, open-label extension (NCT03939312) monitored receiving 60 mg once daily, followed by four-week follow-up period. Results Of 685 taking at least...

Thirty five printers who had work related wheeze, chest tightness, or breathlessness kept two hourly records of their peak expiratory flow for at least weeks. They all worked in a factory supplied by air from contaminated humidifiers. The showed consistent deterioration 15 workers, nine whom diurnal variation exceeding 20%. Ten workers further after the humidifiers been cleaned, other practices remaining unchanged. There was substantial improvement 10 implying that material humidifier cause...

Background Ubrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine. This trial evaluated safety and tolerability ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing to healthy participants. Methods In this phase 1, multicenter, double-blind, parallel-group trial, adults (age 18–50 years) were randomized 1:1 placebo or ubrogepant. was dosed at 100 mg (2 × 50...

Twelve patients with skin vasculitis complicating cystic fibrosis are described. Seven of these were proven histologically and two had systemic vascultitis. Staining vasculitic tissue by the avidin-biotin immunoperoxidase technique using both monoclonal polyclonal antisera directed against Haemophilus influenzae, staphylococcus aureus Pseudomonas aeruginosa did not consistently reveal any bacterial antigens in tissues. In one patient appeared secondary to ranitidine. There was no evidence...

Abstract Objective To determine the potential efficacy of ubrogepant for acute treatment migraine based on historical experience with triptans. Background Although triptans have improved treatment, their and tolerability may limit utility in some individuals. Ubrogepant is a small‐molecule, oral calcitonin gene–related peptide receptor antagonist approved by Food Drug Administration adults. Methods This post hoc analysis pooled data from pivotal trials ACHIEVE I II, identically designed,...

To evaluate the efficacy, safety, and tolerability of atogepant versus placebo in a phase 2b/3 trial for prevention episodic migraine.

<h3>Background and Objectives</h3> To examine the efficacy of ubrogepant in treatment migraine with mild vs moderate or severe pain. <h3>Methods</h3> This was a phase 3, open-label, dose-blinded, 52-week extension trial. Adults were randomized 1:1:1 (usual care, 50 mg, 100 mg). Participants treated up to 8 attacks any pain intensity every 4 weeks. Efficacy outcomes (only collected for ubrogepant) included 2-hour freedom (2hPF), from associated symptoms, disability. A generalized linear mixed...

<h3>Importance</h3> Some patients with migraine, particularly those in primary care, require effective, well-tolerated, migraine-specific oral preventive treatments. <h3>Objective</h3> To examine the efficacy of atogepant, an oral, small-molecule, calcitonin gene–related peptide receptor antagonist, using 4 levels mean monthly migraine-day (MMD) responder rates. <h3>Design, Setting, and Participants</h3> This secondary analysis a phase 3, double-blind, placebo-controlled randomized clinical...

Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine in adults. These analyses evaluated proportions clinical trial participants who experienced sustained responses to atogepant over 12 or 52 weeks treatment.

<h3>Objective:</h3> To evaluate the efficacy, safety, and tolerability of ubrogepant 100 mg when administered during prodrome (premonitory phase) a migraine attack. <h3>Background:</h3> Ubrogepant is calcitonin gene-related peptide (CGRP) receptor antagonist approved for acute treatment migraine. The earliest phase attack characterized by symptoms other than aura, which precede onset headache. This study examined potential ubrogepant, prodrome, to prevent or attenuate headache disability....

Summary A total of 601 sera from groups workers exposed to heavily and moderately contaminated humidifiers respectively were examined by the double diffusion test for precipitating antibodies humidifier extracts. Clinical information was obtained using a standardized questionnaire. Skin‐prick tests control, three common inhalant antigens an extract performed in 103 subjects humidifier. In this environment strong inverse relationship between current smoking precipitins detected ( P &lt;...

Objective: To evaluate the efficacy, safety, and tolerability of ubrogepant for acute treatment migraine. Background: Ubrogepant, a novel, orally active, calcitonin gene–related peptide receptor antagonist, is in development Design/Methods: Multicenter, double-blind, phase 3 study (NCT02867709). Adults with history migraine were randomized (1:1:1) to placebo or (25mg 50mg). Patients had 60 days treat single attack (moderate/severe pain intensity). Co-primary efficacy endpoints (2h post...

<h3>Objective:</h3> To evaluate efficacy, safety, and tolerability of atogepant for preventive treatment chronic migraine (CM). <h3>Background:</h3> Atogepant is an oral CGRP receptor antagonist approved in the US episodic migraine. <h3>Design/Methods:</h3> PROGRESS(NCT03855137) was a 12-week phase 3 trial adults with CM who were randomized to (30mg twice daily [BID], 60mg once [QD]) or placebo. Primary efficacy endpoint change from baseline mean monthly days (MMDs) over 12 weeks. A key...

Objective: Evaluate efficacy of a second dose ubrogepant for the acute treatment migraine. Background: Ubrogepant is an oral CGRP receptor antagonist in development Two doses separated over time sometimes needed migraine management. Design/Methods: ACHIEVE-I (NCT02828020) and ACHIEVE-II (NCT02867709) were single-attack, Phase 3 trials. Adults with history migraine, with/without aura randomized 1:1:1 to placebo or (50mg 100mg, ACHIEVE-I; 25mg 50mg, ACHIEVE-II). An optional was allowed...